December 2

Neoadjuvant immunotherapy has begun to show benefit for the treatment of patients with rectal cancer as well as for those with colorectal cancer.

Progress in the development of chimeric antigen receptor T-cell therapy and other cell-based therapies has led to new therapeutic options for advanced malignancies. CAR T-cell agents approved by the FDA in recent years include axicabtagene ciloleucel for diffuse large B-cell lymphoma and tisagenlecleucel for both DLBCL and acute lymphoblastic leukemia. 

Early-stage skin cancers that remain localized are often successfully treated through a variety of surgical techniques as well as radiation therapy, photodynamic therapy, and topical chemotherapy, but advanced cases that are beyond surgery may respond to immunotherapies. This setting will be discussed during the Society for Immunotherapy of Cancer’s 34th Annual Meeting.

The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.